Top Page
Fortis Healthcare Ltd.
(FORTIS)
Fortis Healthcare Ltd. (FORTIS) vs. iShares MSCI India ETF (INDA)
Fortis Healthcare Ltd. Business Overview & Revenue Model
Fortis Healthcare Ltd. Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.34B | 77.86B | 68.97B | 62.98B | 57.18B | 40.30B |
| Gross Profit | 36.84B | 45.86B | 39.73B | 23.08B | 32.25B | 20.72B |
| EBITDA | 18.18B | 15.00B | 11.87B | 10.37B | 9.96B | 3.47B |
| Net Income | 10.14B | 7.74B | 5.99B | 5.89B | 5.55B | -1.10B |
Balance Sheet | ||||||
| Total Assets | 150.13B | 136.92B | 132.89B | 124.34B | 118.85B | 111.55B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 5.08B | 6.00B | 3.66B | 4.13B | 4.16B |
| Total Debt | 31.95B | 24.75B | 11.55B | 9.26B | 12.55B | 15.31B |
| Total Liabilities | 53.20B | 45.22B | 47.33B | 43.33B | 48.76B | 44.37B |
| Stockholders Equity | 94.29B | 89.17B | 76.63B | 72.42B | 61.78B | 61.20B |
Cash Flow | ||||||
| Free Cash Flow | 800.30M | 5.77B | 1.58B | 3.75B | 6.50B | 2.67B |
| Operating Cash Flow | 6.76B | 14.24B | 11.00B | 8.22B | 8.65B | 4.85B |
| Investing Cash Flow | -9.86B | -7.79B | -8.86B | -3.74B | -5.14B | -1.35B |
| Financing Cash Flow | 2.46B | -7.14B | -864.58M | -4.71B | -5.17B | -1.43B |
Fortis Healthcare Ltd. Technical Analysis
Fortis Healthcare Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹338.27B | 75.82 | ― | 0.24% | 14.72% | 8.37% | |
66 Neutral | ₹1.08T | 50.39 | ― | 0.27% | 13.66% | 41.32% | |
66 Neutral | ₹223.37B | 68.44 | ― | 0.89% | 10.80% | 32.79% | |
61 Neutral | ₹619.18B | 86.12 | ― | 0.11% | 15.33% | 54.62% | |
61 Neutral | ₹96.25B | 60.35 | ― | 0.21% | 15.41% | 5.93% | |
59 Neutral | ₹853.45B | 55.46 | ― | 0.04% | 23.22% | -19.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Fortis Healthcare Ltd. Corporate Events
Fortis Healthcare Ltd. shareholders have approved a new employee stock option scheme, ESOS 2026, through a postal ballot conducted via e-voting in line with regulatory requirements. The scheme covers eligible employees not only of Fortis Healthcare but also of its subsidiary and associate companies, signaling a broad-based equity incentive plan aimed at aligning employee interests with long-term shareholder value.
The voting process, overseen by an independent scrutinizer and supported by KFin Technologies as the e-voting agency, confirmed that all related resolutions were passed with the requisite majority. This approval is expected to strengthen talent retention and motivation across the wider Fortis group, potentially enhancing operational performance and supporting the company’s growth strategy in the competitive healthcare market.
Fortis Healthcare Ltd. shareholders have approved the Fortis Healthcare Limited Employees Stock Option Scheme 2026 through a postal ballot conducted via e-voting. The scheme covers grants of stock options not only to eligible employees of the parent company but also to those of its subsidiary and associate companies, signaling a broader equity-based incentive framework aimed at aligning employee interests across the group.
The voting process was carried out in compliance with the Companies Act, SEBI listing regulations, and relevant Ministry of Corporate Affairs circulars, with an independent scrutinizer overseeing the e-voting and postal ballot procedure. This approval strengthens Fortis Healthcare’s ability to attract, retain, and motivate talent across its wider corporate structure, potentially supporting long-term operational stability and growth.
Fortis Healthcare has informed the stock exchanges about the status of a special window for re-lodgement of transfer requests for physical shares, as mandated by recent SEBI circulars. The company disclosed a report from its Registrar and Share Transfer Agent, KFin Technologies, confirming that no shareholder requests for re-lodgement of physical share transfers were received, processed, approved, or rejected during the specified period, indicating minimal impact on its share transfer operations under this regulatory window.
This disclosure underscores Fortis Healthcare’s compliance with SEBI’s regulatory framework on physical share transfers and provides transparency to investors and regulators on the usage of the special re-lodgement facility. The absence of activity in this window suggests that most shareholders may have already transitioned to dematerialised holdings, reducing operational risk and aligning the company’s shareholder base with broader market moves toward electronic securities.
Fortis Healthcare has announced that its composite scheme of merger by absorption involving several wholly owned subsidiaries has become effective following regulatory filings. The company filed certified orders from the National Company Law Tribunal’s Delhi and Chandigarh benches with the Registrar of Companies on March 1, 2026, bringing the scheme into force.
Under the scheme, Fortis Emergency Services Limited, Fortis Cancer Care Limited, Fortis Health Management (East) Limited, and Birdie & Birdie Realtors Private Limited have been merged into Fortis Hospitals Limited. The consolidation is expected to streamline the group’s corporate structure and internal operations by integrating these businesses under a single hospital-focused entity.
Fortis Healthcare has announced a series of in-person investor and analyst meetings in the United States in January 2026, including a non-deal roadshow in New York and Boston organized by J.P. Morgan and participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco. The sessions, which will feature one-on-one and group meetings focused on general business and industry updates, underscore the company’s efforts to deepen engagement with global investors, enhance transparency, and potentially strengthen its visibility and positioning within the international healthcare investment community, while confirming that no unpublished price-sensitive information will be shared and related presentations will be publicly disclosed in advance.
Fortis Healthcare has announced a series of upcoming investor and analyst interactions, including an in-person non-deal roadshow organized by J.P. Morgan in New York and Boston on January 12–13, 2026, and participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026. These one-on-one and group meetings, aimed at providing a general business and industry update without sharing unpublished price-sensitive information, underscore the company’s efforts to deepen engagement with global investors and analysts, potentially enhancing its visibility and positioning in international capital markets.
Fortis Healthcare Limited has announced a schedule of upcoming investor and analyst interactions in the United States, including a non-deal roadshow organized by J.P. Morgan in New York and Boston on January 12–13, 2026, and participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026. The meetings, to be held in person through one-on-one and group formats, are intended to provide a general business and industry update, with the company emphasizing that no unpublished price-sensitive information will be shared and that the related investor presentation will be disclosed to stock exchanges in advance, underscoring its focus on regulatory compliance and transparent engagement with global investors.
Fortis Healthcare’s wholly owned subsidiary, International Hospital Limited, has signed definitive agreements to acquire TMI Healthcare Private Limited, which primarily comprises hospital operations, along with the underlying hospital land, building and an adjacent land parcel in Bengaluru. The deal, which centers on the People Tree Hospital in Yeshwanthpur (with related facilities to be carved out before closing), aligns with Fortis’s cluster-focused growth strategy and is intended to further consolidate its network and competitive position in the Bengaluru healthcare market, though completion remains subject to customary conditions precedent and closing conditions.
Fortis Healthcare has signed definitive agreements to acquire the 125-bed People Tree Hospital in Yeshwanthpur, Bengaluru, through its wholly owned subsidiary International Hospital Limited by purchasing 100% of TMI Healthcare Private Limited and related real estate assets for a cumulative transaction value of INR 430 crore, including debt. The deal, which is expected to close by the end of January 2026, includes the acquisition of an adjacent 0.8-acre land parcel that will allow Fortis to expand the facility to more than 300 beds, supported by an additional planned investment of about INR 410 crore over the next three years in infrastructure, medical equipment and clinical programs such as radiation oncology; this move strengthens Fortis’s cluster-based expansion strategy in Bengaluru, enhancing its presence from the current 900 beds toward a potential 1,500-plus beds across seven facilities and positioning the company to grow revenues and profitability from the hospital’s existing business base.